CALL/NOVO-NORDISK B/1400/0.1/21.06.24 | Real-time BOERSE MUENCHEN 10:25:59 2024-06-12 EDT | ||
| 0.001 EUR | 0.00% |
|
| 6 months | -88.89% | ||
| Current year | -90.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-12 | 0.001 | 0.00% |
| 24-06-11 | 0.001 | 0.00% |
| 24-06-10 | 0.001 | 0.00% |
| 24-06-07 | 0.001 | 0.00% |
| 24-06-06 | 0.001 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 12, 2024 at 10:25 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GQ4VDX |
| ISIN | DE000GQ4VDX7 |
| Date issued | 2023-09-13 |
| Strike | 1,400 kr |
| Maturity | 2024-06-21 (9 Days) |
| Parity | 10 : 1 |
| Emission price | 0.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.141 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.149 € |
| Spread % | 99.33% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
982
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.35%
- Stock Market
- Warrants
- Warrant
